PAVmed to Present at Canaccord Genuity Growth 41st Annual Conference

NEW YORK, 05 August 2021– (COMMERCIAL THREAD) –PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, today announced that Lishan Aklog, MD, President and CEO of PAVmed will provide an update on the company at the 41st Canaccord Genuity Growth Conference on August 11, 2021 at 5:00 p.m. EDT.

To access the live webcast of the presentation, please Click here. A replay will be available after the presentation and accessible in the Investor Relations section of the PAVmed website.

About PAVmed

PAVmed Inc. is a highly differentiated, multi-product, commercial-stage medical technology company with a diverse product portfolio addressing unmet clinical needs encompassing a wide range of clinical areas with attractive regulatory pathways and market opportunities. Principal subsidiary, Lucid Diagnostics Inc., markets the first and only commercial tool for the widespread early detection of precancer and esophageal cancer – EsoGuard® Esophageal DNA test and EsoCheck® Esophageal cell collection device. Its GI Health division also includes the complementary esophageal ablation device EsoCure â„¢ with Caldus â„¢ technology. Its Minimally Invasive Interventions division markets its CarpX® Minimally invasive device for carpal tunnel syndrome. Another major subsidiary, Veris Health Inc., is a digital health company developing the first smart implantable vascular access port with biological sensors and wireless communication to improve personalized cancer care through remote patient monitoring. . Other divisions include Infusion Therapy (PortIO â„¢ implantable intraosseous vascular access device and NextFlo â„¢ intravenous infusion kit) and Emerging Innovations (non-invasive laser blood glucose monitoring, pediatric ear tubes and mechanical circulatory support). For more information, please visit, Follow us on Twitter, connect with us on LinkedIn, and watch our videos on Youtube. For more information on our majority owned subsidiary, Lucid Diagnostics Inc., please visit, follow Lucid on Twitter, and connect with Lucid on LinkedIn. For detailed information on EsoGuard, please visit and follow us on Twitter, Facebook and Instagram.

Forward-looking statements

This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. These forward-looking statements, based on the current beliefs and expectations of PAVmed’s management, are subject to risks and uncertainties, which could cause actual results to differ from forward-looking statements. The risks and uncertainties that may cause such differences include, among others, the volatility of the price of PAVmed common shares, Series W warrants and Series Z warrants; general economic and market conditions; uncertainties inherent in research and development, including the cost and time required to advance PAVmed’s products to regulatory submission; whether regulatory authorities will be satisfied with the design and results of the preclinical studies of PAVmed; if and when PAVmed’s products are authorized by regulatory authorities; market acceptance of PAVmed products once authorized and marketed; our ability to raise additional funds and other competitive developments. PAVmed has not yet received clearance from the FDA or other regulatory body to market many of its products. The Company is monitoring the COVID-19 pandemic and its impact on our business. The Company expects the significance of the COVID-19 pandemic, including the extent of its effects on the Company’s financial and operating results, to be dictated, among other things, by the success of efforts to contain it and the impact of the measures taken in response. New risks and uncertainties can arise from time to time and are difficult to predict. All of these factors are difficult or impossible to predict accurately and many of them are beyond the control of PAVmed. For a more detailed list and description of these and other risks and uncertainties that may affect PAVmed’s future operations, see Part I, Article IA, “Risk Factors”, in the most recent PAVmed Annual Report. on Form 10-K filed with the Securities and Exchange Commission, as it may be updated in Part II, Item 1A, “Risk Factors” in any Quarterly Report on Form 10-Q filed by PAVmed after its report most recent annual. PAVmed disclaims any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in its expectations or in the events, conditions or circumstances on which such expectations may be based, or which may affect the likelihood that actual results differ from those contained in forward-looking statements.

See the source version on


Mike Havrilla
Director of Investor Relations
(814) 241-4138
[email protected]

Katie Gallagher / Kristi Bruno
(617) 792-3937 / (617) 865-3940
[email protected]

Previous SUBJECT PAGE: Sustainability in the Fertilizer Industry
Next Nanofabrication offers valuable solutions for storing renewable energies

No Comment

Leave a reply

Your email address will not be published.